https://www.ncbi.nlm.nih.gov/pubmed/20647199 [1] (full text)
https://www.ncbi.nlm.nih.gov/pubmed/20647198 [2] (full text)
https://www.ncbi.nlm.nih.gov/pubmed/25372085 [3] (full text)
https://www.ncbi.nlm.nih.gov/pubmed/22729997 [4] (full text)
https://www.ncbi.nlm.nih.gov/pubmed/25477054 [5] (full text)
https://www.ncbi.nlm.nih.gov/pubmed/24609057 [6] (full text)
https://www.ncbi.nlm.nih.gov/pubmed/25556904 [7]
https://www.ncbi.nlm.nih.gov/pubmed/23001900 [8] (full text)
https://www.ncbi.nlm.nih.gov/pubmed/26167726 [9]
https://www.ncbi.nlm.nih.gov/pubmed/27482943 [10]
[1] Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. The New England journal of medicine 2010 Jul 15;363(3):221-32 (full text)
[2] Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. The New England journal of medicine 2010 Jul 15;363(3):211-20 (full text)
[3] Guillevin L, Pagnoux C, Karras A et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. The New England journal of medicine 2014 Nov 6;371(19):1771-80 (full text)
[4] Smith RM, Jones RB, Guerry MJ et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and rheumatism 2012 Nov;64(11):3760-9 (full text)
[5] Alberici F, Smith RM, Jones RB et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford, England) 2015 Jul;54(7):1153-60 (full text)
[6] Turner-Stokes T, Sandhu E, Pepper RJ et al. Induction treatment of ANCA-associated vasculitis with a single dose of rituximab. Rheumatology (Oxford, England) 2014 Aug;53(8):1395-403 (full text)
[7] Roberts DM, Jones RB, Smith RM et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. Journal of autoimmunity 2015 Feb;57:60-5
[8] Fabris M, Quartuccio L, Vital E et al. The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. Arthritis and rheumatism 2013 Jan;65(1):88-97 (full text)
[9] Kim SH, Jeong IH, Hyun JW et al. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. JAMA neurology 2015 Sep;72(9):989-95
[10] Cartin-Ceba R, Indrakanti D, Specks U et al. The pharmacogenomic association of Fcγ receptors and cytochrome p450 enzymes and response to treatment with rituximab or cyclophosphamide in Anti-Neutrophil Cytoplasmic Antibody-Associated vasculitis. Arthritis & rheumatology (Hoboken, N.J.) 2016 Aug 2;
Per inserire una domanda, segnalare la tua esperienza, un tuo commento o una richiesta di precisazione fai il login con il tuo nome utente e password.
Se non lo sei ancora puoi registrati partendo da qui.